Business Wire

Chappellet Becomes the Only American Winery to Be Named a Relais & Châteaux Preferred Partner

7.2.2023 17:00:00 EET | Business Wire | Press release

Share

Napa Valley’s acclaimed Chappellet winery ( www.chappellet.com ) is excited to announce that it has been invited to become a Relais & Châteaux Preferred Partner. With this honor, Chappellet becomes the first American winery to be invited to become a Preferred Partner and joins an exclusive list of some of the world’s top wineries to be named a Relais & Châteaux Partner. Established in 1954, Relais & Châteaux is an association of more than 580 hotels and restaurants around the world operated by independent innkeepers, chefs, and owners who share a passion for excellence and a desire for authenticity in their relationships with their clientele. Preferred Partners are selected based on their shared values with Relais & Châteaux and their ability to provide unique and unforgettable experiences in their signature areas of expertise. “As a multigeneration, family-owned-and-operated winery that shares Relais & Châteaux's values and passion for excellence, we are thrilled to build on our longstanding relationship with Relais & Châteaux as a Preferred Partner,” said Cyril Chappellet, the second-generation president and chairman of Chappellet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005010/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

View of Chappellet’s renowned estate vineyard on Pritchard Hill. (Photo: Business Wire)

Founded in 1967 by legendary vintners Donn and Molly Chappellet, Chappellet was the second post-Prohibition winery established in the Napa Valley. Inspired by the notion that “Bacchus loves the hills,” the Chappellet family settled on Pritchard Hill in the eastern mountains of Napa Valley, where they became some of the earliest pioneers of high-elevation vineyard planting. Though grapes grown above 1,000 feet represent only approximately 3% of total production in California, mountain-grown wines represent a significant portion of the most iconic and sought-after wines in America. Still independent and family-run today, Chappellet’s mountain-grown Cabernet Sauvignons from Pritchard Hill have earned global renown and are recognized as benchmarks for their region, having received multiple 100-point scores and glowing comparisons to the First Growths of Bordeaux from top wine critics.

“Since 1967, our family’s winery on Pritchard Hill has been dedicated to crafting world-class, mountain-grown Cabernet Sauvignon,” added Cyril Chappellet. “Like each Relais & Châteaux property, we strive for perfection in everything we do, from the meticulous way we organically farm our vineyard to the deep and enduring bonds we forge with our customers. Over the years, we have enjoyed remarkable relationships with many Relais & Châteaux owners and properties in North America. We look forward to building on these strong connections as we grow our presence around the globe.”

Chappellet has been partnering with a number of Relais & Châteaux properties in North America over the past decade, hosting curated weekends for their collectors at prestigious properties that include Triple Creek Ranch in Montana, The Wauwinet in Nantucket, Massachusetts, Planters Inn in Charleston, South Carolina and Auberge du Soleil in Napa Valley, California.

“I have had the pleasure of working with Chappellet at multiple Relais & Châteaux properties for the last 15 years,” said Molly Smith, the general manager of Triple Creek Ranch. “The history, familiarity, and elegance that the winery has carried through to the guests has elevated experiences and memories.”

As a Preferred Partner, Chappellet will be hosting additional special “Collectors’ Weekends” for both Relais & Châteaux members and Chappellet collectors at Relais & Châteaux properties throughout North America in 2023. The winery will also be developing new ways to engage with Relais & Châteaux members and its global association of restaurants and hotels, including vintner dinners, tasting events, wine education experiences, and the expansion of Chappellet’s “Collectors’ Weekends” into Europe and Asia.

In commenting on Chappellet’s new status as a Preferred Partner, David Fink, the proprietor of Relais & Châteaux property L'Auberge Carmel, said, “More than half a century ago, Donn Chappellet left his corporate life in Los Angeles to find one of the most idyllic places to raise a family and become a wine grower. Today, the Chappellet family carries Donn's vision forward and has created some of the most special wines made in California.”

About Chappellet
In 1967, on the advice of legendary winemaker André Tchelistcheff, the Chappellet family settled on the steep slopes of Pritchard Hill© and founded Chappellet, becoming just the second post-Prohibition winery in Napa Valley. As pioneers of high-elevation vineyard planting, Chappellet has earned acclaim for crafting benchmark wines with an emphasis on mountain-grown Cabernet Sauvignons, while establishing Pritchard Hill as one of the world’s great wine regions.

About Relais & Châteaux - A Movement with Meaning
Relais & Châteaux, established in 1954, is an association of 580 unique hotels and restaurants throughout the world, owned and operated by independent entrepreneurs – most often families – who are passionate about their craft and deeply committed to forging warm, lasting relationships with their guests. Relais & Châteaux members protect and promote the wealth and diversity of the world’s culinary and hospitality traditions, to ensure they continue to thrive. They are equally dedicated to preserving local heritage and the environment, as articulated in the association’s Vision presented to UNESCO in November 2014. For more information, visit www.relaischateaux.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sonia Ginsburg
Sonia@jam-pr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye